In the treatment of NSCLC, the amplification of MET induces resistance toward the TKI targeting the epidermal growth factor receptor (EGFR), and combined therapy of EGFR-TKI and MET-TKI has shown significant efficacy [28]. Here, EGFR is linked to non-small cell lung carcinoma.